Physician profile
Veeda O Landeras
NPI 1306045646
$5,420.32
in general payments reported to CMS, 2019-2025
21 companies · $965 in 2025
The $965 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $110 · 2021: $222 · 2022: $1,959 · 2023: $589 · 2024: $1,086 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619 · Education: $21.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.91 |
| Education | $21.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $1,789.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $895.07 | 2019-2025 | Farxiga |
| Amgen INC. | $364.19 | 2019-2024 | Krystexxa, Epogen, Aranesp |
| Calliditas Therapeutics US INC. | $333.43 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $326.62 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $319.14 | 2022-2025 | |
| Horizon Therapeutics Plc | $287.11 | 2023 | Krystexxa |
| Travere Therapeutics, INC. | $262.97 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $197.53 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $136.85 | 2022-2025 | Lupkynis |
| Lilly USA, LLC | $105.77 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $78.79 | 2019-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.48 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $58.26 | 2019-2020 | |
| Ardelyx, INC. | $56.21 | 2024-2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $32.91 | 2024 | Ultomiris |
| Allergan, INC. | $32.10 | 2019 | |
| Fisher & Paykel Healthcare INC | $27.27 | 2019 | |
| Ascendis Pharma Endocrinology INC | $22.25 | 2025 | Yorvipath |
| Scpharmaceuticals INC. | $18.44 | 2025 | |
| Vifor Pharma, INC. | $15.75 | 2023 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veeda Landeras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.